|
Haleon PLC on Wednesday announced a decline in first-quarter revenue, mostly reflecting promotional activity in North America, while revenue in its Oral Health segment, which includes toothpaste Sensodyne, grew. The Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 said revenue fell 2.3% to £2.85 billion in the first quarter of 2025 from £2.92 billion a year ago. Revenue in its Oral Health unit was up 3.0% to £880 million from £854 million. However, revenue in Digestive Health & Other was down 16% at £431 million compared to £511 million in the first quarter of 2024. This reflected the disposals of ChapStick and of the nicotine replacement business outside the US, Haleon said. Haleon confirmed its 2025 guidance, still expecting organic revenue growth of 4% to 6% and organic growth in operating profit to be ahead of organic revenue growth. Separately, Haleon said it has added Matt Shattock to its board as an independent non-executive director starting June 1. Shattock was chair of Domino’s Pizza Group PLC from 2020 until last week. Haleon shares were down 0.5% at 375.40 pence each on Wednesday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
